Drug Designing: Open Access

Drug Designing: Open Access
Open Access

ISSN: 2169-0138

+441414719275

Gjumrakch Aliev

Gjumrakch Aliev

Gjumrakch Aliev
Professor of Cardiovascular, Neuropathology and Gerontology
University of Atlanta, USA

Biography

Dr. Alliev is born on September 01, 1958 and is citizen of USA. He is currently President and CEO "GALLY” International Biomedical Research Consulting LLC. He is also Editor in Chief of other Journals like Open Journal Psychiatry, World Journal of Neuroscience, Applied Cell Biology. He also serves as an Chairman of Internationl Division of EuroEspes Biomedical Research Center on Spain and Vice chairman of EuroEspes Chair of Biotechnology & Genomics in Spain. He is also Professor of Cardiovascular, Neuropathology, Gerontology, Health Science and Healthcare Administration, Associate Director- Doctor of Science Program in Health Science and Healthcare Administration and Member of International Advisory Council/Board, University of Atlanta Monograph Series. He is Fluent in English, Russian, Azeri, Spanish, Italian and French. He completed his PhD in Cardiovascular Biology and Pathology, Neuroscience: Moscow State University, Moscow, Russia.

Research Interest

The present research interest includes Cell Biology, Biochemistry, and Functional Morphology of Cell and Tissues: Endothelial cells, Smooth Muscle Cells; Neurons and as well as Glial and Macrophages Cells. Specific characteristic changes of cell biochemical properties and morphology in different functional states; particularly atherogenesis, vascular remodeling, hypertension, ischemia/reperfusion, tumor angiogenesis, signal transduction and mitochondria DNA deletion and/or overproliferation during cancer growth, metastases and Alzheimer’s diseases;  Regulation biochemical mechanisms of specific nitric oxide synthase (NOS) expression in endothelial and smooth muscle cells and macrophages in vivo and in vitro;   At the present time, my lab is investigating the cellular and subcellular ultrastructural and molecular mechanisms of the features in the changes of mitochondria (DNA deletion, Cytochrome C Oxidase activity, redox activity (Fe), as well as protein modification and oxidation (HNE) and RNA (8HOG) oxidation during normal aging, atherosclerosis, tumor angiogenesis, stroke, human AD and transgenic mouse models of AD by using molecular biology and functional and structural methods (e.g., in situ hybridization and immunocytochemistry techniques at the light and electron microscopic levels). In addition, the biochemical properties of these protein activities will also be considered for our future studies.  One of our newer research interests focuses on investigating the interaction of nanoparticles with tissues and cells. We have recently developed ways to determine the biological effects of nanoparticles in vivo and in vitro by utilizing animal models of human diseases. Our goal is to not only elucidate the pathogenic mechanisms underlying the nanoparticleseffects, but to also discover potential new drug development strategies. For example, our ongoing "In vitro Cancer Cell Line as a Model for the Peptide based new Drug Development" study has so far showed promising results regarding the specific delivery of drugs to tumor tissues. In another of our in vivo studies, we have found that nanoparticles are able to cross the blood brain barrier (BBB), which has been the biggest impediment in delivering drugs to patients with Alzheimers disease. We are using classical biochemistry, cell biology, and morphology techniques in conjunction with more modern methods, such as SEM/TEM SED X-ray elemental analysis and NMR studies of protein structure and dynamics, macromolecular interactions, mechanistic enzymology, and computational analyses and modeling, in order to determine the exact nature of the relationship between the nanoparticles and the underlying tissue.

Top